Search results
Metis Global Partners LLC Sells 549 Shares of Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 2 days ago(NASDAQ:INCY – Free Report) by 6.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,746 shares of the biopharmaceutical company’s stock ...
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
Digital Journal· 7 days ago(NASDAQ:SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be participating in the EF Hutton Annual Global Conference, which will take ...
Stevanato Group S.p.A. (NYSE:STVN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 12 hours agoStevanato Group S.p.A. (NYSE:STVN) Q1 2024 Earnings Call Transcript May 11, 2024 Stevanato Group...
Ocular Therapeutix (NASDAQ:OCUL) PT Lowered to $14.00 at HC Wainwright
ETF DAILY NEWS· 2 days agoThe firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also recently issued reports on the company. Piper Sandler ...
Earnings call: Arcus Biosciences Reports Strong Q1 2024 Performance By Investing.com
Investing.com· 3 days agoArcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, reported a robust...
A Radnor biopharma firm laid off 20% of its workforce
Philly.com· 4 days agoMarinus Pharmaceuticals Inc., a Radnor biopharmaceutical company developing treatments for rare...
Stifel Nicolaus Downgrades MacroGenics (NASDAQ:MGNX) to Hold
ETF DAILY NEWS· 18 hours agoMacroGenics (NASDAQ:MGNX – Get Free Report) was downgraded by Stifel Nicolaus from a “buy” rating to a “hold” rating in a report released on Friday, MarketBeat Ratings reports. Stifel Nicolaus ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoCompany to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage & ...
Brokers Set Expectations for ACADIA Pharmaceuticals Inc.’s Q2 2024 Earnings (NASDAQ:ACAD)
ETF DAILY NEWS· 3 days agoLeerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of $0.09 for the quarter, down from their prior forecast ...
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
Yucaipa News Mirror· 3 days agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs ...